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Abstract
Background Eculizumab is approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use off-label is
frequently reported. The aim of this study was to describe the broader use and outcomes of a cohort of pediatric patients exposed
to eculizumab.
Methods A retrospective, cohort analysis was performed on the clinical and biomarker characteristics of eculizumab-exposed
patients < 25 years of age seen across 21 centers of the Pediatric Nephrology Research Consortium. Patients were included if they
received at least one dose of eculizumab between 2008 and 2015. Traditional summary statistics were applied to demographic
and clinical data.
Results A total of 152 patients were identified, mean age 9.1 (+/−6.8) years. Eculizumab was used “off-label” in 44% of cases.
The most common diagnoses were aHUS (47.4%), Shiga toxin-producing Escherichia coli HUS (12%), unspecified thrombotic
microangiopathies (9%), and glomerulonephritis (9%). Genetic testing was available for 60% of patients; 20% had gene variants.
Dosing regimens were variable. Kidney outcomes tended to vary according to diagnosis. Infectious adverse events were the most
common adverse event (33.5%). No cases of meningitis were reported. Nine patients died of noninfectious causes while on
therapy.
Conclusions This multi-center retrospective cohort analysis indicates that a significant number of children and young adults are
being exposed to C5 blockade for off-label indications. Dosing schedules were highly variable, limiting outcome conclusions.
Attributable adverse events appeared to be low. Cohort mortality (6.6%) was not insignificant. Prospective studies in homoge-
nous disease cohorts are needed to support the role of C5 blockade in kidney outcomes.
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Introduction
Eculizumab (Soliris®, Alexion Pharmaceuticals, Cheshire,
CT, USA) is a recombinant, humanized monoclonal antibody
directed against human complement component C5. It inhibits
the function of the terminal complement pathway by binding
C5 and preventing the cleavage of C5 into C5a (a potent
anaphylatoxin) and C5b, the first protein of the membrane
attack complex (MAC) [1–3]. The efficacy of eculizumab
for the treatment of atypical hemolytic syndrome (aHUS)
was first described in 2009 [4–8]. Subsequent data from both
uncontrolled (case reports) and controlled (clinical trials) fur-
ther established the safety and efficacy of eculizumab in this
setting [9–12]. Eculizumab received approval for the treat-
ment of aHUS by the European Medicines Agency (EMA)
in July 2009 and by the US Food and Drug Administration
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(FDA) in September 2011 [13]. Where available, eculizumab
has become the standard of care for treating aHUS as well as
other rare diseases: paroxysmal nocturnal hemoglobinuria
(PNH), neuromyelitis optica spectrum disorder (NMOSD),
and refractory myasthenia gravis [14].
Eculizumab has appeared in a number of case reports
describing off-label use, particularly in diseases that are
presumed to have dysregulated complement activity as a
part of their underlying pathology. Single-center publi-
cations exist for the off-label use of eculizumab in (1)
Shiga toxin-producing Escherichia coli hemolytic ure-
mic syndrome (STEC HUS) [15–19], (2) hematopoietic
stem cell transplantation-associated thrombotic microan-
giopathy (TMA) [20, 21], (3) complement-mediated glo-
merulonephritis (GN) [22–31], and (4) antibody-
mediated kidney allograft rejection (AMR) [32–44].
Until results become available from prospective, ran-
domized control trials in these presumed abnormal com-
plement activity disorders, practitioners will continue to
rely on small case series, single-center studies, and case
reports to guide their use of eculizumab for off-label
indications. Circumstantial data reporting such as this
is heavily influenced by publication bias—particularly
as it applies to the over-reporting of positive outcomes.
We conducted a multi-center retrospective chart review
to describe the spectrum of eculizumab use in children
and young adults in the USA from 2008 to 2015. Our
goal was to understand the contemporary use of termi-
nal complement blockade, including indications, dosing
practices, kidney outcomes, and adverse events.
Methods
Twenty-one (of 60) Pediatric Nephrology Research
Consortium (PNRC) centers volunteered to participate in this
study. All centers were governed by local IRB. Patients were
identified from the medical records of participating centers.
All patients ≤ 25 years of age who received at least one dose
of eculizumab between August 1, 2008 and July 31, 2015
were included in the study. Data collection ended on
July 31, 2015.
Six hundred and eleven data points were collected on
each patient (REDCap ©- University of Iowa) including
demographics, diagnoses and disease characteristics, re-
ported indication and prescribing information for
eculizumab, genetic testing results, adverse events dur-
ing therapy, and estimated glomerular filtration rate
(eGFR) and urine protein. See Fig. 1 for the schematic
of the disease classification, genetic testing, treatment
duration, and kidney outcomes in the 152 patients.
Diagnoses were defined per institution and included
atypical hemolytic uremic syndrome (aHUS), Shiga
toxin-producing Escherichia coli HUS (STEC HUS),
non-STEC infection-related TMA, GN, other TMA, par-
oxysmal nocturnal hemoglobinuria (PNH), AMR, and
other diagnoses. Non-STEC infection-related TMA in-
cluded patients with clinical TMA associated with other
or unknown infections. “Patients with other TMA” cap-
tures those with thrombotic microangiopathy that did
not fit into the other available categories.
Genetic variants described in association with aHUS and
included in the study survey were complement factor H
(CFH), membrane cofactor protein (MCP), complement com-
ponent 3 (C3), diacylglycerol kinase-ε (DGKE), complement
factor I (CFI) , complement factor B (CFB) , and
thrombomodulin (THBD).
Estimated GFR was calculated by modified Schwartz
equation (0.413 × Ht(cm)/serum creatinine (mg/dL)) for
patients < 18 years of age and by the CKD-EPI equa-
tion for those > 18 years of age (eGFR = 141 × min
(SCr/κ or 1)
α × max (SCr/κ or 1)
−1.209 × 0.993Age ×
1.018 [if female] × 1.159 [if Black]) [45, 46]. The
eGFR was calculated for patients at initiation and at
the patient’s latest follow-up if available, regardless of
whether they remained on eculizumab. For all patients
on dialysis, eGFR was corrected to 10 mL/min/1.73 m2
and all eGFR values greater than 150 mL/min/1.73 m2
were corrected to 150 mL/min/1.73 m2 based upon pre-
viously published data [47]. The paired difference for
eGFR was calculated by subtracting the eGFR at initia-
tion from the eGFR at latest follow-up.
Proteinuria was quantified by urine protein-to-
creatinine ratio (UPC) (mg/mg), from convenience sam-
ples or timed urine collections, at initiation and at the
latest follow-up visit. A UPC value of 10 mg/mg was
substituted for all UPC values greater than 10 mg/mg
based upon the median and range data and the lack of
clinical significance of a UPC far above nephrotic range
proteinuria (2 mg/mg). The paired difference for UPC
was calculated by subtracting the UPC at initiation from
the UPC at latest follow-up. Medians were calculated
for both eGFR and UPC paired difference given skewed
distribution. Eculizumab-exposed patients were excluded
from eGFR and UPC analysis if they received the agent
prophylactically in preparation for kidney transplant or
if they received a kidney transplant between initiation of
eculizumab and latest follow-up.
Categorical variables were summarized using frequencies
and percentages. Continuous variables were summarized by
measures of central tendency. Signed ranked tests were used
to calculate p-values for kidney outcome data. Statistical sig-
nificance was defined as a p-value of < 0.05, but our main goal
was to evaluate direction and potential impacts for guiding




We identified 152 patients from 21 centers within the PNRC
who were exposed to eculizumab during the designated peri-
od. The mean age at eculizumab initiation was 9.1 ± 6.8 years
(range 0.1–25 years). Fourteen of the patients (9%) were be-
tween the ages of 18 and 25 at the time of eculizumab initia-
tion. Fifty-three percent of patients were male, 67.1% were
Caucasian, 13.2% African-American, and 19.7% other. The
most frequent diagnosis associated with eculizumab exposure
was aHUS (47.4%) (Fig. 2, panel a). Forty-four percent of the
patients in our cohort received eculizumab for off-label indi-
cations including STEC HUS (11.8%), non-STEC infection-
related TMA (3.3%), other TMA (9.2%), GN (9.2%), AMR
(6.6%), and other (3.9%). The most common indication for
eculizumab use in patients with STEC HUS and non-STEC
infection-related TMA was neurologic impairment (43.4%)
and risk of death (13%). The identified indications for initia-
tion of eculizumab use in GN were progressive kidney failure
(67%), proteinuria (53%), hypertension (20%), concern for
TMA (13%), and disease recurrence after transplantation
(7%). The non-STEC infection-related TMA category includ-
ed one patient with non-Shiga toxin-producing E. coli 0157,
one with Clostridium septicum bacteremia, and three with
unknown infections. Within the other TMA group, the major-
ity of the patients (9) who received eculizumab were designat-
ed as hematopoietic stem cell transplant TMA-related patients
(64.3%) with three thrombotic thrombocytopenic purpura
(TTP) patients (21.4%), one patient with TMA secondary to
systemic lupus erythematosus, and one patient with TMA
from an unknown etiology. GN diagnoses, as reported by
the local provider, included seven patients with C3GN
(50%), five with dense deposit disease (35.7%), and two with
membranoproliferative GN (14.3%). In this cohort, ten pa-
tients with various forms of solid organ transplantation (3
kidney, 1 combined liver/kidney, 4 heart, and 1 lung) received
eculizumab for AMR.
Genetic testing was performed per local practice preference
and was available for 91 (59.8%) of the 152 patients. Thirty-
one patients of 91 tested (20.4%) possessed DNA variants in
CFH, CFI, C3, MCP, THBD, and/or DGKE. The authors
made no attempt to confirm the relative pathogenicity of these
reported DNA variants. CFH variants (45.2%) were the most
commonly reported of the 31 positively identified variants,
followed by C3 (19.3%), MCP (19.3%), THBD (6.5%),
DGKE (6.5%), and CFI (3.2%) gene variants. Of the 62
aHUS patients who had genetic testing, 37 patients did not
have a reported abnormality in these gene variants (Fig. 2
panel b). However, four patients with GN (12.9%) were found
to have gene variants (two with CFH and two with C3 gene
variants) and two patients with other TMAs (6.5%) were
found to have gene variants (one with MCP and one with
THBD gene variants). No DNA variants in the aforemen-
tioned genes were reported in STEC HUS or PNH patients.
Treatment characteristics
Therapy duration was available for 143 of the 152 patients.
The date of initiation was unknown for one child and the date
of the latest eculizumab dose was unknown in eight. The
median length of therapy for known patients was 5.25 months
(IQR 1.1, 22.2), 14.7 months for aHUS patients (IQR 4.7,
29.1), and 1.8 months (IQR 0.2, 1.8) for STEC HUS patients.
At the time of data collection, 67 patients were still on
Fig. 1 Overall schematic of the
disease classification, genetic
testing, treatment duration, and
renal outcomes in the 152
children from 21 different centers
within the Pediatric Nephrology
Research Consortium study who
had received eculizumab therapy
from 2008 to 2015
eculizumab therapy with a median length of eculizumab ther-
apy of 21.1 months (IQR 6.1, 32.4). Of the patients on
eculizumab at study end, 83% (56/67) were for approved in-
dications (aHUS and PNH).
Seventy-six patients were exposed to eculizumab but were
no longer on the agent at the time of data collection. Median
length of therapy for this group was 1.6 months (IQR 0.5, 5.1).
Seven patients received only one dose of eculizumab (1
aHUS, 3 STEC HUS, 1 non-STEC infection-related HUS, 1
AMR, and 1 other). Therapy was discontinued in 16/72 aHUS
patients for the following reasons: disease improved (75%),
kidney function did not recover (19%), physician preference
(31%), patient or parent preference (12.5%), negative genetic
testing (6%), and one patient was treated per protocol for 1
year following kidney transplantation. For those receiving
eculizumab for off-label indications, therapy was discontinued
for disease improved (33%), kidney function not recoverable
(19%), patient preference (14.3%), per AMR protocol
(14.3%), physician preference (4.7%), adverse events of ther-
apy (9.5%), and no response to therapy (4.7%). Five patients
were restarted on eculizumab after discontinuation; two
patients were off therapy for 1 month or less and three patients
were off for 12 or more months. These five particular patients
were taken off eculizumab therapy due to disease improve-
ment (80%), physician preference (40%), or kidney function
was non-recoverable (20%). Indications for restarting
eculizumab therapy for the five patients who underwent stop
and restart therapy were worsened kidney function (40%),
disease recurrence (40%), and genetic mutation later identified
(40%).
One hundred and two patients (67.1%) were dosed as per
the aHUS dosing recommendations [14], 46 patients (30.2%)
followed an alternative dosing regimen, and in 4 patients
(2.6%), the dosing was unclear from the medical record. The
explanations for alternative dosing regimens included physi-
cian preference (17%), critical illness (13%), re-dosing after
plasmapheresis (15%), PNH regimen (12.8%), hematopoietic
stem cell transplant TMA regimen (8.5%), transplant protocol
(10.6%), STEC HUS (4.2%), frequent relapses (2%), dense
deposit disease (2%), NMOSD (2%), and unknown (13%).
Nine out of ten patients with AMR were not dosed per guide-
lines. Eighty-six percent of aHUS patients were reported to be
Fig. 2 Disease characteristics of patients treated with eculizumab within
the Pediatric Nephrology Research Consortium from 2008 to 2015. a
Provider reported diagnoses in children treated with terminal
complement blockade. *The glomerulonephritis category includes
patients with C3 GN, dense deposit disease, and membranoproliferative
GN. **The other TMA category includes patients with hematopoietic
stem cell transplant TMA, thrombotic thrombocytopenic purpura
(TTP), TMA secondary to systemic lupus erythematosus, and TMA
from an unknown etiology. ***The other category captures all
remaining indications. b DNA variants reported in those patients
diagnosed with atypical hemolytic uremic syndrome. Sixty-two atypical
hemolytic uremic syndrome patients underwent genetic testing. Twenty-
five DNA variants were identified, across 6 different genes and 37
patients did not have a reported abnormality in these gene variants. The
authors made no attempt to confirm the relative pathogenicity of reported
DNA variants
dosed according to current aHUS guidelines but in the remain-
der of the aHUS patients (9/72), the guidelines were modified
for alternative dosing for physician preference (33.3%), peri-
transplant protocol (22.2%), critical illness (11.1%), relapse
requiring higher/more frequent dosing (11.1%), and unknown
(22.2%).
Kidney outcomes with eculizumab therapy
Estimated GFR (eGFR) was available in 130/152 patients at
initiation, and 128/152 patients at the latest follow-up visit.
Thirteen patients had no eGFR data available at initiation,
15 had no eGFR data available at latest follow-up, and nine
patients were excluded as they received kidney transplants in
association with eculizumab initiation. Paired data analysis
was performed in 120 patients (Fig. 3). The median eGFR of
the paired analysis was 18.8 mL/min/1.73 m2 (IQR 10, 67.8)
for all diagnoses at initiation and 94.4 mL/min/1.73 m2 (IQR
55.9, 119.8) at the latest follow-up visit whether or not they
remained on eculizumab therapy. The median eGFR for
aHUS patients increased by 73.8 mL/min/1.73 m2 (IQR
15.1, 106.6) from eculizumab initiation to the latest follow-
up (p < 0.05) over a median follow-up time of 21.3 months
(IQR 5.4, 32.4). Median eGFR improved by 68.44 mL/min/
1.73 m2 in STEC HUS (p < 0.05) over a median follow-up
time of 11.7 months (IQR 5.4, 26.2). There were no statisti-
cally significant differences in eGFR at initiation and latest
follow-up in patients with all other diagnoses. The number
of patients on dialysis for all diagnoses improved from 53 at
initiation of eculizumab therapy to 23 at the latest follow-up (7
aHUS, 3 STEC HUS, 5 other TMA, 5 GN, 2 AMR, and 1
other). However, there were a greater number of patients re-
ceiving dialysis at latest follow-up as compared to the time of
initiation of eculizumab therapy for the diagnoses of other
TMA (5), GN (5), and AMR (2).
Proteinuria data were available in 58/152 patients at initia-
tion and in 64/152 patients at latest follow-up. Paired data
analysis was performed in 39 patients (Fig. 4). The overall
median UPC ratio from eculizumab initiation was 6.1 mg/g
(IQR 1.7, 10) and at latest follow-up 0.4 mg/g (IQR 0.2, 1.1).
The UPC ratio demonstrated statistically significant improve-
ment from initiation to latest follow-up among patients with
aHUS (paired difference UPC of −5 mg/g (IQR −9.6, −0.4))
and other TMA (paired differenceUPC of −9mg/g (IQR −9.5,
−1.5)) (p < 0.05). Patients with STEC HUS, other non-STEC
infection-related HUS, GN, AMR, and other diagnoses
Paired difference eGFR (Latest Follow Up - Iniaon)
Diagnosis 66 18 5 14 13 8 13 6
Paired N 54 17 4 12 12 7 9 5
Paired Difference
eGFR* 73.8( 15.1, 106.6) 73.3( 65.9, 106.1) 86.4( 70.4, 116.0) 0.0( -2.2, 28.5) 5.2( -11.7, 49.6) -18.9( -56.7, 0.0) -5.8( -23.4, 1.2) 0.0( 0.0, 3.1)
Range -29.87, 140.00 0.00, 122.46 69.16, 130.92 -58.66, 49.85 -69.46, 86.23 -78.95, 53.13 -53.00, 31.47 -42.61, 32.99



































FU Months* 21.3( 5.4, 32.4) 11.7( 5.4, 26.2) 7.2( 5.1, 9.3) 5.8( 3.3, 9.9) 16.9( 13.2, 31.1) 8.8( 4.4, 12.0) 23.4( 17.3, 46.1) 5.4( 2.1, 8.8)
Fig. 3 Median estimated glomerular filtration (eGFR) at initiation and at
follow-up by diagnosis for pediatric patients receiving eculizumab from
2008 to 2015. *Median with interquartile range. #p values were
calculated using signed rank test. aHUS: atypical hemolytic uremic
syndrome, STEC HUS: Shiga toxin-producing Escherichia coli
hemolytic uremic syndrome, non-STEC Inf: non-Shiga toxin-producing
Escherichia coli infection-related thrombotic microangiopathy, TMA:
other thrombotic microangiopathy, GN: glomerulonephritis, AMR:
antibody-mediated rejection, PNH: paroxysmal nocturnal
hemoglobinuria, other
demonstrated improvements in UPC ratios from initiation to
latest follow-up, but the differences were not statistically
significant.
Adverse events reported after eculizumab therapy
Overall 34.9% (53/152) of the cohort experienced at least one
infectious adverse event following eculizumab initiation and
17.8% experienced a noninfectious adverse event following
initiation of eculizumab (Table 1). There were 46 bacterial
infection events among 40 persons (26.3%) during the
follow-up period. Central line infections were the most fre-
quent bacterial infections (26.1% of all bacterial infections).
The other bacterial infections were blood stream infection,
pneumonia, urinary tract infections, endocarditis, tracheitis,
pharyngitis, groin abscess, cellulitis, and peritonitis. Two pa-
tients (1.3%) experienced an infection caused by an encapsu-
lated organism, and this included a Streptococcus pneumoniae
central line infection and a Klebsiella pneumoniae urinary
tract infection and central line infection in a single patient.
No patient was diagnosed with an infection due to Neisseria
meningitides. Nineteen (12.5%) patients received meningo-
coccal polysaccharide vaccination and 111 (73%) received
meningococcal conjugate vaccine prior to eculizumab therapy
initiation. There were 24 viral infection events in 22 (14.5%)
patients during the follow-up period. The most frequent viral
infection that patients experienced was influenza A (20.8% of
all viral infections). Other viral infections observed were cy-
tomegalovirus, BK virus, Epstein-Barr virus, human herpes-
virus-6, norovirus, herpes simplex virus, varicella, and un-
known viral upper respiratory tract infections. Twenty-seven
(17.8%) patients in the entire cohort were reported to experi-
ence 44 noninfectious adverse events after initiation of
eculizumab. The most commonly reported adverse events af-
ter eculizumabwere nausea and abdominal pain (13.6% each).
The other noninfectious adverse events reported were infusion
reactions (6.8%), hypertension (6.8%), headache (6.8%),
vomiting (6.8%), back pain (4.5%), diarrhea (4.5%), and ane-
mia (4.5%). There were 31.8% other noninfectious adverse
events reported after eculizumab initiation and included one
patient each reporting fever, fatigue, constipation, body aches,
dizziness, chest pain, and edema.
Ten patients (6.6%) died during the follow-up period. Nine
died while still on therapy. One patient with atypical HUS
died several months after discontinuation of therapy. Death
was most common in the other TMA group (5/14, 35.7%);
there were two deaths in those with STEC HUS (2/18,
11.1%), and one death in aHUS patients (1/72, 1.4%). Of
Paired difference UPC (Latest Follow Up - Iniaon)
Diagnosis 62 18 5 12 13 8 13 5
Paired N 20 0 2 6 9 1 0 1
Paired Difference UPC* -5.0( -9.6, -0.4) NA -6.6( -9.2, -4.0) -8.4( -9.5, -1.5) -0.9( -4.0, 0.3) -4.5( -4.5, -4.5) NA -2.4( -2.4, -2.4)
Range -21,0.01 NA -9.2, -4.0 -9.0,-0.41 -7.9, 1.8 -4.5,-4.5 NA -2.35,-2.35
P Value# <0.0001 NA 0.5000 0.0313 0.2031 1.000 NA 1.000
FU Months* 17.9( 4.5, 29.8) 11.2( 1.8, 13.2) 3.1( 1.8, 7.6) 3.8( 2.3, 8.4) 13.7( 6.3, 24.4) 4.4( 0.3, 21.9) NA 4.0( 4.0, 4.0)
Fig. 4 Median urine protein-to-creatinine (UPC) at initiation of
eculizumab and at follow-up by diagnosis for pediatric patients
receiving eculizumab from 2008 to 2015. *Median with interquartile
range. #p values were calculated using signed rank test. aHUS: atypical
hemolytic uremic syndrome, STEC HUS: Shiga toxin-producing
Escherichia coli hemolytic uremic syndrome, non-STEC Inf: non-Shiga
toxin-producing Escherichia coli infection-related thrombotic
microangiopathy, TMA: other thrombotic microangiopathy, GN:
glomerulonephritis, AMR: antibody-mediated rejection, PNH:































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the nine patients who died while receiving eculizumab thera-
py, the causes of death were reported as cardiac arrest (n = 5),
central nervous system hemorrhage (n = 3), and viral infection
(n = 1). No patient deaths were attributed to bacterial
infections.
Discussion
Our study characterizes the use of eculizumab within the
North American pediatric population and demonstrates that
although the majority of pediatric patients receiving
eculizumab are diagnosed with aHUS, a significant proportion
of pediatric eculizumab use is also for off-label indications
(44%). Dosing practices varied widely based upon the indica-
tion for eculizumab and reasons for deviation from the recom-
mended aHUS dosing guidelines were widely variable.
Though kidney outcomes appeared to improve for some pa-
tients receiving eculizumab by specific diagnosis, given the
wide variation in follow-up times, and lack of power to study
this, conclusions regarding kidney outcomes cannot be fully
drawn from this study. Participants were reported to have few
adverse events and a low number of infections in this cohort.
Similar to the French national hospitalization database re-
port which revealed that 50% of eculizumab use was for non-
EMA-approved indications [48], our study indicates that 44%
of eculizumab use in our pediatric cohort was for off-label
indications [14]. The four most common non-FDA-approved
indications for eculizumab use in our cohort were STECHUS,
AMR, GN, and other TMA. This study did not address if the
use of eculizumab was clinically indicated or how the clini-
cianwas able to get authorization for the off-label use; we only
have the diagnosis and in some cases, a brief response on why
the local clinician felt complement inhibition was indicated.
This data collected in 2015 likely represents contemporary
use of eculizumab, as the current approved indications have
not significantly changed during the period of data collection
with the exception of approval of eculizumab for myasthenia
gravis in 2017 [14]. The data from this study was insufficient
to fully define the efficacy of the terminal complement block-
ade in off-label indications or define a clear dosing strategy in
these disorders.
Given the heterogeneity of the patient diagnoses and the
variability of therapy duration in this cohort, it is difficult to
offer a summary comment on the significance of the reported
kidney outcomes. Several patients (7) received only one dose
of eculizumab, this occurred most commonly in patients with
STEC HUS, and the most common reason for eculizumab
therapy discontinuation was for disease improvement. Our
aHUS population showed a significant improvement in
eGFR similar to other reported studies [49–52].
Interestingly, eculizumab was discontinued in approximately
1 in 5 aHUS patients (22%) in this cohort, which may be
secondary to the higher frequency of aHUS patients without
identified genetic variants (47/72, 65.2%). Prior literature sug-
gests a low risk of disease recurrence in aHUS patients with-
out identified genetic variants [53]. STEC HUS was the only
off-label diagnosis with a significant increase in the eGFR;
however, this study was not designed to assess kidney func-
tion during the acute phase of this illness. Our data likely
represents improvement in eGFR at latest follow-up as a nat-
ural progression of STEC HUS and this is not necessarily
indicative of response to eculizumab. The reported rates of
stage 5 chronic kidney disease and need for transplantation
are low for STEC HUS (1.4–7.3%) [54–57], but 17% of pa-
tients remained on dialysis in our cohort. This leads us to
believe that our cohort of STEC HUS patients had more se-
vere disease courses. It is likely that the disease severity and
increased risk of mortality drove most clinicians to consider
eculizumab therapy. No significant trend in eGFR was noted
in the other off-label indications, likely due to the heterogene-
ity of diagnoses, eculizumab dosing strategies, and the vari-
able follow-up period. Proteinuria improved from the time of
therapy initiation to the time of the most recent urinalysis for
all diagnoses but this difference was only significant for
aHUS. The number of urine protein measurements was very
low or absent for several diagnoses. Whether the kidney out-
comes, strictly speaking, reflect the general natural history of
pediatric patients with acute disease or a terminal pathway
targeted aspect of the individual diseases (anti-complement
or anti-inflammation) is unknown.
Genetic testing was performed in 60% of the cohort per
local practice preference. Not all patients with aHUS re-
ceived genetic testing and this may have reflected avail-
ability of testing in early 2000s when some patients of
this cohort were diagnosed. Lower rates of genetic testing
by other diagnoses likely reflect practice variation in off-
label use of eculizumab.
What is perhaps more salient is the fact that our data reca-
pitulate formerly published safety data, suggesting that
eculizumab is well tolerated [49–52]. Infectious and noninfec-
tious adverse event rates in this cohort were similar to pub-
lished safety data and no serious safety events were noted.
Though we assessed adverse events listed as potential adverse
events from eculizumab’s manufacturer, we are unable to de-
termine if the reported adverse events in this cohort were spe-
cifically related to medication exposure or underlying disease-
related morbidity (i.e., central venous catheters, dialysis).
While the mortality rate in this study was 6.6% for all diagno-
ses, the mortality rate in this cohort was 1.4% in aHUS pa-
tients, and this is similar to the previously reported mortality
for patients with aHUS on eculizumab therapy of 0-2% [49,
58]. The mortality of the STEC HUS patients was 11.1%
which is higher than previously reported rates in the literature
which range from 1.3 to 5% [54–57]. This may reflect that
patients in this cohort had more significant disease severity as
evidence by 43% of patients having severe neurologic impair-
ment at time of eculizumab initiation.
A strength of this study is the number of centers involved in
data collection. This combined with the fact that all exposed
patients at the enrolled PNRC centers were included lends to-
ward reduced reporting bias. We ultimately decided to include
young adult patients along with pediatric patients so as to in-
crease the number of patients enrolled in this study and to
include more variety in diagnoses, including C3GN which typ-
ically presents at a later age. It is our impression that this study
provides a realistic description of practices and outcomes.
The primary weakness of this report is the retrospective
nature of the data, particularly as it applies to the fact that local
practice styles heavily influenced use of the agent. The lack of
homogeneous use patterns and the variable time period until
most recent follow-up in addition to the lack of a control
population makes the interpretation of the findings difficult.
Additionally, the number of patients for each off-label diag-
nosis was small.
In conclusion, we found that a significant number of pediatric
patients are being exposed to C5 blockade for off-label indica-
tions. Dosing schedules are highly variable. Kidney outcomes
are favorable in most. Although this study was not designed to
show efficacy of eculizumab for off-label indications, it was able
to show that the attributable adverse events and mortality with
eculizumab in pediatric patients appear to be low.
Until such time when we fully understand the role of the
terminal complement pathway (or associated anaphylatoxins)
in the underlying pathogenesis of the various diseases, it will
be difficult to create homogenous test populations. The num-
ber of publications involving off-label use of eculizumab con-
tinues to grow. These studies continue to consist mainly of
single-center case reports or case series, which have an inher-
ent positive bias; thus, the overall strength of evidence for
eculizumab use in these indications remains low. More infor-
mation is needed to determine the efficacy and effective dos-
ing of eculizumab for these kidney diagnoses where terminal
complement blockade is not yet the standard of therapy.
Without homogenous disease cohorts (at least in some aspect
of their disease), it may be difficult to reliably detect targeted
outcomes. Medical practice patterns that allow varied patient
characteristics and varied exposure protocols will continue to
seriously limit the true scientific understanding of the efficacy
of terminal complement blockade. Thus, we anxiously await
the results of two ongoing prospective randomized trials of
eculizumab in pediatric STEC HUS (NCT02205541 in
France; ECUSTEC in the UK) and similar trials for other
complement-medicated diseases. Additionally, randomized
controlled trials are currently being conducted for long-
acting eculizumab (ravulizumab, ALXN1210) and other new-
ly developed complement inhibitors with proposed use in
C3GN, DDD, immune complex membranoproliferative GN,
lupus nephritis, IgA nephropathy, and membranous
nephropathy which we hope will guide therapy with comple-
ment inhibition in the future.
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